Cargando…

Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities

BACKGROUND: Advanced age and underlying comorbidities are associated with greater rates of recurrence in patients with Clostridioides difficile infection (CDI). Reducing the likelihood of recurrence through treatment with an antimicrobial followed by a microbiota replacement therapy can decrease the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tillotson, Glenn, Archbald-Pannone, Laurie, Johnson, Stuart, Ng, Samson, Ando, Masakazu, Harvey, Adam, Bancke, Lindy, Feuerstadt, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846189/ https://www.ncbi.nlm.nih.gov/pubmed/36686631 http://dx.doi.org/10.1093/ofid/ofac703

Ejemplares similares

236. Treatment of Recurrent Clostridioides difficile Infection With RBX2660 in Patients ≥ 65 Years Old With Underlying Comorbidities
por: Tillotson, Glenn S, et al.
Publicado: (2022)

167. Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies
por: Bancke, Lindy, et al.
Publicado: (2021)

522. Significant Improvement in Health-Related Quality of Life (HRQL) with RBX2660: Results from a Phase 3 Randomized, Placebo-Controlled Trial in Recurrent Clostridioides Difficile Infection (PUNCH CD3)
por: Feuerstadt, Paul, et al.
Publicado: (2022)

1042. Safety of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies
por: Braun, Tricia, et al.
Publicado: (2021)

Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent Clostridioides difficile Infection: Results From the PUNCH CD3 Clinical Trial
por: Garey, Kevin W, et al.
Publicado: (2023)

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
por: Khanna, Sahil, et al.
Publicado: (2022)

Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA(TM)) Administered Under Enforcement Discretion to Patients With Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2023)

Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2023)

129. Antimicrobial Resistance Genes Were Reduced Following Administration of Investigational Microbiota-Based Live Biotherapeutic RBX2660 to Individuals with Recurrent Clostridioides difficile Infection
por: Hau, Heidi, et al.
Publicado: (2021)

Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
por: Khanna, Sahil, et al.
Publicado: (2022)

The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660
por: Orenstein, Robert
Publicado: (2022)

LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections
por: Orenstein, Robert, et al.
Publicado: (2019)

1064. Treatment Success in Reducing Recurrent Clostridioides difficile Infection with Investigational Live Biotherapeutic RBX2660 Is Associated with Microbiota Restoration: Consistent Evidence from a Phase 3 Clinical Trial
por: Blount, Ken, et al.
Publicado: (2021)

Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
por: Orenstein, Robert, et al.
Publicado: (2023)

Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
por: Orenstein, Robert, et al.
Publicado: (2022)

Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of RBX2660: An Investigational Microbiome Restoration Therapeutic
por: Blount, Ken F, et al.
Publicado: (2019)

669. Twelve-Month Durability of Microbiota-Based Therapy RBX2660 for Prevention of Recurrent Clostridium difficile Infection
por: Jones, Courtney, et al.
Publicado: (2019)

670. VRE Clearance in Patients with Recurrent Clostridium difficile Infection Following Treatment with Microbiota-Based Drug RBX2660
por: Hau, Heidi, et al.
Publicado: (2019)

1039. Rapid Restoration of Bile Acid Compositions After Treatment with RBX2660 for Recurrent Clostridioides difficile Infection—Results from the PUNCH CD3 Phase 3 Trial
por: Papazyan, Romeo, et al.
Publicado: (2021)

Safety of fecal microbiota, live-jslm (REBYOTA(™)) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials
por: Lee, Christine, et al.
Publicado: (2023)

Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection
por: Dubberke, Erik R., et al.
Publicado: (2022)

Effect of fecal microbial transplantation on Clostridioides difficile infection: dysbiosis, metabolites and health related quality of life
por: Garey, Kevin W, et al.
Publicado: (2023)

Survey of C. difficile-Specific Infection Control Policies in Local Long-Term Care Facilities
por: Archbald-Pannone, Laurie
Publicado: (2014)

Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent Clostridium Difficile Infection is Associated with More Pronounced Alterations in Microbiome Profile
por: Khanna, Sahil, et al.
Publicado: (2017)

29. Rapid Restoration of Bile Acid Compositions After Treatment with Investigational Microbiota-based Therapeutic RBX2660 for Recurrent clostrioides Difficile Infection
por: Ferdyan, Nicky, et al.
Publicado: (2020)

Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota–Based Therapeutic
por: Berenson, Charles S, et al.
Publicado: (2023)

Clostridioides difficile infection: microbe-microbe interactions and live biotherapeutics
por: Wang, Ruojun
Publicado: (2023)

468 RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study
por: Dubberke, Erik, et al.
Publicado: (2014)

A Risk Score to Predict Clostridioides difficile Infection
por: Aukes, Laurie, et al.
Publicado: (2021)

RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients’ Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections
por: Khanna, Sahil, et al.
Publicado: (2020)

The Clinical Burden of Clostridioides difficile in Ontario, Canada
por: Pereira, Jennifer A, et al.
Publicado: (2019)

Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial
por: Kwak, Suryang, et al.
Publicado: (2020)

Gut microbiota and microbiota-based therapies for Clostridioides difficile infection
por: Chopra, Teena, et al.
Publicado: (2023)

Propensity-Matched Cost of Clostridioides difficile Infection Overdiagnosis
por: Madden, Gregory R, et al.
Publicado: (2020)

Transitions of care in Clostridioides difficile infection: a need of the hour
por: Khanna, Sahil, et al.
Publicado: (2022)

Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection
por: Chaar, Abdelkader, et al.
Publicado: (2021)

1950. Prevention of Recurrent Clostridium difficile at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study
por: Mische, Sarah, et al.
Publicado: (2018)

The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota
por: Zhang, Yongrong, et al.
Publicado: (2022)

Treating Clostridioides difficile: Could Microbiota-based Live Biotherapeutic Products Provide the Answer?
por: Nagarakanti, Sandhya, et al.
Publicado: (2023)

Outcomes of a Multidisciplinary Clinic in Evaluating Recurrent Clostridioides difficile Infection Patients for Fecal Microbiota Transplant: A Retrospective Cohort Analysis
por: Shin, Jae Hyun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0gmgb8forkge8a86bqfgleiok7